Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Encore Vision

- PMLiVE

Gilead lead NASH drug flunks phase 3 test

Analysts suspect the setback could prompt Gilead to license other candidates

- PMLiVE

Galapagos expands presence in fibrosis, NASH with Evotec deal

As lead candidate filgotinib nears filing, firm looks to expand horizons

- PMLiVE

Gilead awaits CEO and readouts to revive fortunes

NASH and oral RA drugs set for crucial readouts

Roche Basel Switzerland

Roche submits Kadcyla for FDA Real-Time review

Aims to extend use in breast cancer patients

AstraZeneca AZ

US, EU regulators back rapid reviews of AZ’s RSV med

Positive top-line data triggered speedy assessments

- PMLiVE

CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL

Novartis agrees pricing deal with NHS England

- PMLiVE

GSK’s Advair Diskus faces first generic in US

Analysts predict around $250m in sales for Wixela Inhub this year

- PMLiVE

Nerve centre gives Novartis edge in clinical trials

Algorithms predict potential delays

- PMLiVE

Novartis aims for 10 blockbuster launches by 2020

Includes new gene therapy Zolgensma

Credit Score

Asking patients to prove they can pay for healthcare is inhumane. Period.

Novartis Gehry Building

Novartis forges AI alliance with Oxford University

Part of Novartis drive to become 'data-driven' pharma company

- PMLiVE

NICE rejects Novartis migraine treatment Aimovig

A draft 'no' to first-in-class treatment, despite discount

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links